GSK1363089
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for GSK1363089, covering 2017-07-07 to 2023-08-04. Get the full timeline:
Most recent: Clinical Trial Update: MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy [Phase 1, Phase 2]